Trabedersen
- Generic Name
- Trabedersen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 925681-61-4
- Unique Ingredient Identifier
- 98OYR854NY
- Indication
Investigated for use/treatment in brain cancer, colorectal cancer, melanoma, and pancreatic cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 45
- Registration Number
- NCT06579196
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 27
- Registration Number
- NCT00761280
- Locations
- 🇦🇷
FLENI, Ciudad Autónoma de Buenos Aires, Argentina
🇺🇸NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath